Valuation: Atrion Corporation

Market Cap 809M 693M 649M 594M 1.11B 77.45B 1.13B 7.66B 2.99B 38.9B 3.04B 2.97B 129B P/E 2022
28.6x
P/E 2023 34.4x
Enterprise Value 803M 688M 644M 589M 1.11B 76.87B 1.12B 7.61B 2.97B 38.62B 3.02B 2.95B 128B EV / Sales 2022
5.27x
EV / Sales 2023 3.9x
Free-Float
50.88%
Yield 2022
1.47%
Yield 2023 2.3%
3 years 274.98
Extreme 274.98
503.24
5 years 274.98
Extreme 274.98
805.62
10 years 274.98
Extreme 274.98
948.03
Manager TitleAgeSince
Corporate Secretary 53 20/08/2024
Director TitleAgeSince
Director/Board Member 53 20/08/2024
Date Insider Type Main position Quantity % Market Cap.
21/08/24 Issuer sale

Director

2,991 0.1699%
21/08/24 Issuer sale

Chief Executive Officer

98,614 5.6032%
21/08/24 Issuer sale

Director

499 0.0284%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%-.--%-.--%-5.30% 809M
+2.19%+4.84%-11.64%+12.29% 202B
+1.14%+2.28%+2.47%+14.39% 119B
+1.06%+1.34%+4.88%+75.73% 60.69B
-1.37%-6.57%+28.86%+58.31% 52.38B
+2.33%+4.69%-2.35%-30.34% 52.3B
+2.35%+2.89%+14.54%-11.79% 34.85B
+5.16%-4.14% - - 30.06B
-0.20%+1.05%+45.52%-10.08% 24.85B
-0.29%-3.87%-6.22%+24.74% 23.84B
Average +1.24%+0.25%+8.45%+14.22% 60.11B
Weighted average by Cap. +1.53%+1.90%+1.96%+17.84%

Financials

2022 2023
Net sales 184M 157M 147M 135M 253M 17.56B 256M 1.74B 678M 8.82B 689M 674M 29.17B 169M 145M 136M 124M 233M 16.2B 236M 1.6B 625M 8.14B 636M 622M 26.92B
Net income 35.01M 29.99M 28.06M 25.68M 48.2M 3.35B 48.84M 332M 129M 1.68B 131M 129M 5.57B 19.41M 16.63M 15.56M 14.24M 26.73M 1.86B 27.08M 184M 71.68M 933M 72.89M 71.3M 3.09B
Net Debt -25.21M -21.6M -20.21M -18.5M -34.71M -2.41B -35.17M -239M -93.1M -1.21B -94.66M -92.61M -4.01B -6.02M -5.15M -4.82M -4.41M -8.28M -576M -8.39M -56.97M -22.22M -289M -22.59M -22.1M -956M
Logo Atrion Corporation
Atrion Corporation develops and manufactures products, primarily for medical applications. The Company's medical products are used in a number of fields including fluid delivery, cardiovascular, and ophthalmic applications. It has developed a variety of proprietary valves designed to precisely fill, hold, and release and/or remove controlled amounts of fluids, including blood and drugs, or gasses on demand for use in areas such as intubation, intravenous, catheter, and other applications in fields including anesthesia and oncology. The core of its cardiovascular products is its Myocardial Protection System, a technology that is the only open-heart surgery system that delivers to the heart essential fluids and medications, mixes critical drugs, and controls temperature, pressure, and other important variables. The Company also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults.
Employees
712
  1. Stock Market
  2. Stocks
  3. ATRI Stock